Initial dosimetry from the randomized Phase 2 OPTIMAL-PSMA study indicates TLX597-Tx delivers higher tumor uptake with low salivary gland and kidney exposure, a profile Telix argues supports dose intensification without a commensurate rise in off-target toxicity. The readout, presented at IPCS 2026, comes from men with advanced mCRPC and is being used to justify moving the small-molecule PSMA radioligand into earlier-stage settings.
The core update: TLX597-Tx (177Lu-DOTA-HYNIC-panPSMA) is being tested in an investigator-initiated, open-label, multi-center trial that randomizes 120 patients 2:1 to an intensified schedule versus a standard regimen. The intensified arm escalates activity to 8.5 GBq per cycle with front-loaded dosing on days 1, 3, and 15, followed by three additional cycles at 10-week intervals. The study is designed to exploit windows of tumor radiosensitivity while tracking organ dosimetry, safety, and efficacy. Based on the early organ-sparing signals, Telix will initiate OPTIMAL-E, a Phase 2 study in metastatic hormone-sensitive prostate cancer, positioning TLX597-Tx for androgen pathway–sensitive disease where quality-of-life and long-term tolerability are decisive.
Strategically, Telix is segmenting prostate cancer with two differentiated PSMA-targeted therapeutics: TLX597-Tx, a small molecule intended to push upstream into mHSPC with a potentially wider therapeutic window, and TLX591-Tx, an antibody-based rADC in Phase 3 (ProstACT Global) for mCRPC. The bet is that organ-sparing dosimetry can enable higher early tumor dosing and earlier-line adoption for TLX597-Tx, while the antibody construct pursues later-line disease and combination strategies. This portfolio approach addresses a clear market tension: RLTs have demonstrated efficacy but face adoption limits from xerostomia and renal toxicity, constraints that become less acceptable in earlier-stage patients who remain on therapy longer and value functional preservation.
For trial operators and sites, the intensification schema has immediate operational consequences. Front-loaded dosing compresses nuclear medicine workflow into the first month, requiring tight coordination with radiopharmacies for 177Lu supply, same-day quality control, and radiation safety staffing. Dosimetry-driven protocols increase imaging burden, with serial SPECT/CT and PSMA PET for patient selection and response, favoring high-capability centers but potentially narrowing the site network. If organ exposure remains low, sites could see reduced reliance on mitigation tactics such as gland cooling and lower supportive care for xerostomia, easing chair time and ancillary resource use. For CROs and sponsors, moving RLTs into mHSPC implies larger, longer trials with rPFS and symptom endpoints, stricter renal monitoring, and payer-directed health economic data given earlier-line cost scrutiny.
Regulators will look for translation from favorable dosimetry to clinically meaningful benefit and consistent safety. In earlier-stage disease, organ risk tolerance tightens, and agencies increasingly expect robust, prospectively collected patient-reported outcomes and functional measures alongside radiographic endpoints. Given ongoing expansion of radiopharmaceutical pipelines, isotope availability, manufacturing scale-out, and cold-chain reliability remain execution risks that can bottleneck both trial conduct and eventual commercialization.
What to watch next: efficacy and safety outputs from OPTIMAL-PSMA beyond dosimetry, including PSA responses, radiographic control, xerostomia incidence, and renal events under the intensified schedule. The OPTIMAL-E design will signal Telix’s regulatory intent in mHSPC—choice of comparator, stratification with concomitant AR pathway inhibitors, and whether dosimetry will guide adaptive dosing. Clarity on 177Lu supply commitments and site enablement will indicate scalability. Finally, how Telix sequences TLX597-Tx with TLX591-Tx will determine whether the portfolio expands total addressable use or risks internal overlap as PSMA-directed therapies migrate earlier in the treatment paradigm.
Source link: https://www.globenewswire.com/news-release/2026/04/29/3284336/0/en/OPTIMAL-PSMA-Trial-of-TLX597-Tx-Next-Generation-RLT-Presented-at-IPCS-2026-Highlighting-Therapeutic-Potential-in-Prostate-Cancer.html
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
